Shares of KalVista (KALV) plunged initially on the report, but have recovered to be down 16c, or 1%, to $11.77.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista trading resumes
- KalVista trading halted, volatility trading pause
- Positive Outlook on KalVista Pharmaceuticals’ Sebetralstat Approval Despite FDA Decision Delay
- Optimistic Buy Rating for KalVista Pharmaceuticals Amid FDA Delay
- KalVista says FDA will not meet PDUFA goal date for Sebetralstat NDA